Brought to you by 
Schering-Plough gets Aveo's AV299 for cancer; ends deal
21 Jul 2014
Executive Summary
Schering-Plough has licensed exclusive global development and marketing rights to Aveo Pharmaceuticals' (oncology therapeutics) AV299. The monoclonal antibody is an antagonist of hepatocyte growth factor/scatter factor (HGF/SF) that has already demonstrated efficacy in preclinical studies.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough gets Aveo's AV299 for cancer; ends deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice